Perclose ProGlide Suture-Mediated Closure System; Perclose ProStyle Suture-Mediated Closure and Repair System
Abbott Vascular, Inc. · Decision date Nov 4, 2026
What did the FDA decide?
FDA’s entry is a supplement to PMA P960043, not a new PMA for the closure systems. The database record identifies the products as Perclose ProGlide Suture-Mediated Closure System and Perclose ProStyle Suture-Mediated Closure and Repair System, and the decision type is a 30-Day Notice.
The described change is limited to manufacturing operations: adding a location for the cuff swaging process in another suite within the same facility. The supplied record does not describe any new indication, clinical data, performance change, or device design change; it only states the process-location change.
FDA approval order statement
adding a location for the cuff swaging process used for Perclose ProGlide Suture-Mediated Closure System and Perclose ProStyle Suture-Mediated Closure and Repair System in another suite in the same facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P960043/S139
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Vascular, Inc.
- Product code
- MGB
- Decision code
- OK30
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Abbott Vascular, Inc.
- Product code
- MGB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960043. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960043 · Original PMA
PROSTAR 9 FR. PERCUTANEOUS VASCULAR SURGICAL (PVS) SYSTEM
P960043/S137 · Related supplement
Perclose ProGlide Suture-Mediated Closure System; Perclose ProStyle Suture-Mediated Closure and Repair System
P960043/S139 received
Application receipt date recorded by FDA.
P960043/S138 · Related supplement
Perclose ProStyle Suture-Mediated Closure and Repair System
P960043/S139 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P960043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA approval | Apr 30, 1997 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
VASCADE 5F Vascular Closure SystemP120016/S043 | Cardiva Medical, Inc. | PMA supplement | Sep 10, 2026 | FDA |
| Vasorum, Ltd. | PMA approval | Jul 20, 2016 | FDA | |
| Cardiva Medical, Inc. | PMA approval | Jan 31, 2013 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 400 Saginaw Dr., Redwood, CA, 94063
Sources and methodology
- Original FDA record: P960043/S139
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




